NASDAQ:CUE

Cue Biopharma News Headlines

$12.28
-0.12 (-0.97 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.96
Now: $12.28
$12.49
50-Day Range
$11.20
MA: $13.31
$15.85
52-Week Range
$10.75
Now: $12.28
$31.69
Volume192,868 shs
Average Volume306,407 shs
Market Capitalization$374.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95

Headlines

Cue Biopharma (NASDAQ CUE) News Headlines Today

SourceHeadline
Berenberg Bank Reaffirms "Buy" Rating for Cue Biopharma (NASDAQ:CUE)Berenberg Bank Reaffirms "Buy" Rating for Cue Biopharma (NASDAQ:CUE)
marketbeat.com - March 17 at 7:41 AM
Were Not Very Worried About Cue Biopharmas (NASDAQ:CUE) Cash Burn RateWe're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
finance.yahoo.com - April 9 at 7:51 AM
 Analysts Expect Cue Biopharma, Inc. (NASDAQ:CUE) Will Post Quarterly Sales of $480,000.00 Analysts Expect Cue Biopharma, Inc. (NASDAQ:CUE) Will Post Quarterly Sales of $480,000.00
americanbankingnews.com - March 28 at 9:46 AM
Traders Purchase Large Volume of Cue Biopharma Call Options (NASDAQ:CUE)Traders Purchase Large Volume of Cue Biopharma Call Options (NASDAQ:CUE)
americanbankingnews.com - March 25 at 6:38 AM
Kenneth Pienta Sells 13,000 Shares of Cue Biopharma, Inc. (NASDAQ:CUE) StockKenneth Pienta Sells 13,000 Shares of Cue Biopharma, Inc. (NASDAQ:CUE) Stock
americanbankingnews.com - March 17 at 5:10 PM
Cue Biopharma (NASDAQ:CUE) Receives Buy Rating from Berenberg BankCue Biopharma (NASDAQ:CUE) Receives Buy Rating from Berenberg Bank
americanbankingnews.com - March 17 at 10:10 AM
Cue Biopharma (NASDAQ:CUE) Announces  Earnings ResultsCue Biopharma (NASDAQ:CUE) Announces Earnings Results
americanbankingnews.com - March 17 at 9:30 AM
Cue Biopharma, Inc. 2021 Q4 - Results - Earnings Call PresentationCue Biopharma, Inc. 2021 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 17 at 5:47 AM
Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business HighlightsCue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
finance.yahoo.com - March 16 at 7:26 PM
Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results  and Recent Business HighlightsCue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
finance.yahoo.com - March 16 at 7:26 PM
Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare ConferenceCue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference
finance.yahoo.com - March 15 at 12:41 PM
Cue Biopharma earnings preview: what Wall Street is expectingCue Biopharma earnings preview: what Wall Street is expecting
markets.businessinsider.com - March 14 at 11:38 AM
Cue Biopharma to Present at the Cowen 41st Annual Health Care ConferenceCue Biopharma to Present at the Cowen 41st Annual Health Care Conference
finance.yahoo.com - March 1 at 9:02 AM
Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael KalosCue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos
finance.yahoo.com - February 25 at 12:08 PM
Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael KalosCue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos
finance.yahoo.com - February 25 at 12:07 PM
What Is The Ownership Structure Like For Cue Biopharma, Inc. (NASDAQ:CUE)?What Is The Ownership Structure Like For Cue Biopharma, Inc. (NASDAQ:CUE)?
finance.yahoo.com - February 23 at 8:51 AM
Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° ConferenceCue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference
markets.businessinsider.com - February 23 at 12:26 AM
Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° ConferenceCue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference
finance.yahoo.com - February 22 at 2:25 PM
Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical DevelopmentCue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development
finance.yahoo.com - February 17 at 9:24 AM
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck CancerCue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
finance.yahoo.com - February 8 at 12:45 PM
7 Stocks With Insider Buying This Week Worth A Look7 Stocks With Insider Buying This Week Worth A Look
finance.yahoo.com - February 6 at 7:47 AM
How Much Are Cue Biopharma, Inc. (NASDAQ:CUE) Insiders Spending On Buying Shares?How Much Are Cue Biopharma, Inc. (NASDAQ:CUE) Insiders Spending On Buying Shares?
finance.yahoo.com - January 9 at 10:05 AM
Is CUE A Good Stock To Buy Now?Is CUE A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 1:29 AM
Do Options Traders Know Something About Cue Biopharma (CUE) Stock We Dont?Do Options Traders Know Something About Cue Biopharma (CUE) Stock We Don't?
finance.yahoo.com - December 7 at 6:24 PM
Insider Buying: The Cue Biopharma, Inc. (NASDAQ:CUE) Independent Director Just Bought 3.9% More SharesInsider Buying: The Cue Biopharma, Inc. (NASDAQ:CUE) Independent Director Just Bought 3.9% More Shares
nasdaq.com - November 29 at 4:05 PM
Cue Biopharma Inc Registered Shs BuyCue Biopharma Inc Registered Shs Buy
markets.businessinsider.com - November 25 at 6:53 PM
Upgrade: Analysts Just Made A Meaningful Increase To Their Cue Biopharma, Inc. (NASDAQ:CUE) ForecastsUpgrade: Analysts Just Made A Meaningful Increase To Their Cue Biopharma, Inc. (NASDAQ:CUE) Forecasts
nasdaq.com - November 25 at 8:51 AM
News Flash: Analysts Just Made A Substantial Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) ForecastsNews Flash: Analysts Just Made A Substantial Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Forecasts
finance.yahoo.com - November 25 at 8:51 AM
Benzingas Top Upgrades, Downgrades For November 24, 2020Benzinga's Top Upgrades, Downgrades For November 24, 2020
finance.yahoo.com - November 24 at 2:03 PM
Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare ConferenceCue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference
finance.yahoo.com - November 23 at 12:59 PM
Cue Biopharma PR Shows Q3 EPS $(0.34) Down From $(0.31) YoY, Sales $704.00K Down From $984.00K YoY; Results Were Out Last Week In A FilingCue Biopharma PR Shows Q3 EPS $(0.34) Down From $(0.31) YoY, Sales $704.00K Down From $984.00K YoY; Results Were Out Last Week In A Filing
benzinga.com - November 20 at 12:57 AM
Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with MerckCue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck
finance.yahoo.com - November 19 at 9:53 AM
Cue Biopharma reports Q3 results, issues update to lead programCue Biopharma reports Q3 results, issues update to lead program
seekingalpha.com - November 18 at 12:40 PM
Cue Biopharma EPS beats by $0.12, misses on revenueCue Biopharma EPS beats by $0.12, misses on revenue
seekingalpha.com - November 17 at 8:15 PM
Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial UpdatesCue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates
finance.yahoo.com - November 17 at 8:15 PM
Cue Biopharma to Present at Upcoming Investor Conferences in November 2020Cue Biopharma to Present at Upcoming Investor Conferences in November 2020
finance.yahoo.com - November 11 at 1:05 PM
Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual MeetingCue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting
finance.yahoo.com - November 9 at 8:47 AM
Did Cue Biopharmas (NASDAQ:CUE) Share Price Deserve to Gain 28%?Did Cue Biopharma's (NASDAQ:CUE) Share Price Deserve to Gain 28%?
finance.yahoo.com - November 3 at 9:40 AM
Cue Biopharma Inc Registered Shs hosts conference call for investorsCue Biopharma Inc Registered Shs hosts conference call for investors
markets.businessinsider.com - October 30 at 12:48 PM
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancers (SITC) 35th Anniversary Annual MeetingCue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
benzinga.com - October 19 at 1:28 PM
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual MeetingCue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting
finance.yahoo.com - October 19 at 8:28 AM
Cue Biopharma IncCue Biopharma Inc
bloomberg.com - October 18 at 5:05 PM
Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein ScaffoldsCue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds
finance.yahoo.com - September 15 at 12:30 PM
Cue Biopharma (CUE) Catches Eye: Stock Jumps 5.2%Cue Biopharma (CUE) Catches Eye: Stock Jumps 5.2%
finance.yahoo.com - September 10 at 12:51 PM
Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In GrowthCompanies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth
finance.yahoo.com - September 4 at 10:54 AM
Cue Biopharma to Present at Upcoming Investor Conferences in September 2020Cue Biopharma to Present at Upcoming Investor Conferences in September 2020
finance.yahoo.com - September 3 at 8:59 AM
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2020 Results - Earnings Call TranscriptCue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - September 1 at 10:07 AM
Cue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial UpdatesCue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates
finance.yahoo.com - August 31 at 11:58 PM
Cue Biopharma EPS beats by $0.05, misses on revenueCue Biopharma EPS beats by $0.05, misses on revenue
seekingalpha.com - August 31 at 6:58 PM
Cue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial UpdatesCue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates
finance.yahoo.com - August 31 at 6:58 PM
Cue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy SummitCue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit
markets.businessinsider.com - August 24 at 2:21 PM
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.